Objective: To investigate whether increasing plasma donepezil concentration further improves cognitive function and neuropsychiatric symptoms without compromising safety in patients with dementia with Lewy bodies (DLB). Methods: We analyzed data from a 12-week phase 3 trial of donepezil (5 and 10 mg/day) in patients with DLB. The contribution of factors affecting plasma donepezil concentration was evaluated using multivariate regression analysis. The relationships between plasma donepezil concentration and efficacy (cognitive function as measured by the Mini-Mental State Examination [MMSE], hallucinations and cognitive fluctuation), or safety (blood pressure, pulse rate, body weight, and parkinsonism as measured by the Unified Parkinson's Disease Rating Scale part III) were assessed by scatterplots and Pearson correlation. Results: The data of 87 patients were used in the analyses. Plasma donepezil concentration increased proportionally with increasing dose from 5 to 10 mg/day. The dose (contribution rate: 0.39, p b 0.0001) and age (contribution rate: 0.12, p = 0.0003) were statistically significant contributing factors affecting plasma donepezil concentration. Plasma donepezil concentration correlated significantly with improvement of MMSE score (p = 0.040), but no significant correlations were found with the change in other tested parameters. Conclusions: Plasma donepezil concentration correlated positively with change in cognitive function without affecting safety, and was affected mainly by dose and to a lesser extent by age. Therefore, for patients in whom safety concerns are not found at donepezil 5 mg/day, increasing the dose to 10 mg/day to increase plasma concentration is worthwhile to further improve cognitive function.
Introduction
Dementia with Lewy bodies (DLB) is the second most common type of dementia after Alzheimer's dementia (AD) [1] . Core features of DLB include parkinsonism and neuropsychiatric symptoms such as hallucinations and cognitive fluctuation, as well as cognitive impairment [2] .
Cholinesterase inhibitors (ChEIs) are used to treat the symptoms of DLB based on its neurochemical features: loss of cholinergic neurons and choline acetyltransferase activity, but well-preserved postsynaptic cortical muscarinic receptors [3, 4, 5] . Galantamine, rivastigmine, and donepezil have been shown to be effective in treating DLB patients in several trials [6, 7, 8, 9, 10, 11, 12, 13, 14, 15] , and donepezil has been approved for treating DLB in Japan. A 12-week, phase 2, randomized controlled trial (RCT) of donepezil in DLB patients demonstrated improved cognitive function (evaluated by the Mini-Mental State Examination [MMSE] ) and neuropsychiatric symptoms (evaluated by Neuropsychiatric Inventory [NPI]) at both 5 and 10 mg/day [11] . In the subsequent open-label extension (OLE) study, 5 mg/day donepezil was well tolerated and improved cognitive function and neuropsychiatric symptoms for up to 52 weeks [8] . In a phase 3 RCT of donepezil in DLB patients, cognitive function was significantly improved by 10 mg/day donepezil without serious safety concerns, although improvement of neuropsychiatric symptoms over placebo was not confirmed, owing to the unexpectedly high improvement in the placebo group [9] . The cognitive function improvement continued up to 52 weeks without an increased risk of clinically significant safety events in both 5 and 10 mg groups in the subsequent OLE study [12] . Improvement of cognitive function and neuropsychiatric symptoms by donepezil appeared to be dose-dependent in the above-mentioned RCTs. However, to the best of our knowledge, the pharmacokinetics (PK), the relationship between plasma concentration and efficacy, and the relationship between plasma concentration and safety of donepezil have not been assessed in DLB patients. Additionally, there are clinical concerns in increasing the ChEI dose in DLB patients, because in theory, ChEIs may cause bradyarrhythmia and worsening of parkinsonism [16, 17, 18, 19] . These concerns and lack of data might deter physicians from increasing the ChEI dose in patients whose cognitive function and/or neuropsychiatric symptoms need further improvement.
To investigate whether higher plasma donepezil concentrations further improve cognitive function and neuropsychiatric symptoms without compromising the safety of DLB patients, we assessed the relationship between plasma donepezil concentration and efficacy or safety parameters, using data derived from the phase 3 RCT of donepezil [9] .
Methods

Data source
We analyzed data from the 12-week RCT phase of the phase 3 study of donepezil in DLB patients [9] . The original study was a 52-week study, which integrated a placebo-controlled, 16-week RCT phase (consisting of a 12-week confirmatory phase followed by a 4-week transition period) and a 36-week OLE phase [9, 12] . Patients were randomly allocated to the placebo, 5 mg/day donepezil, or 10 mg/day donepezil groups. In both donepezil groups, 3 mg/day was administered for the first 2 weeks. For the 10 mg group, the dose was titrated to 5 mg/day for another 4 weeks prior to administering 10 mg/day. Eligibility criteria were as follows: (1) outpatients aged ≥ 50 years, (2) diagnosis of probable DLB according to the consensus diagnostic criteria [2] , (3) mild to moderate-severe dementia (10-26 on the MMSE and a Clinical Dementia Rating of ≥ 0.5), and (4) presence of neuropsychiatric symptoms (NPI-plus [12 items with original NPI-10 items, an item of sleep [20, 21 , and an item of cognitive fluctuation reported as Cognitive Fluctuation Inventory (CFI) [22, 13] ] ≥ 8 and NPI-2 [composite score of NPI hallucinations and CFI] [11] ≥ 1). Exclusion criteria were: (1) Parkinson's disease that was diagnosed at least 1 year prior to the onset of dementia, (2) focal vascular lesions visible on MRI or CT scans that might cause cognitive impairment, (3) other neurological or psychiatric diseases, (4) systolic hypotension (b90 mm Hg), (5) bradycardia (b 50 bpm), (6) sick sinus syndrome, (7) atrial or atrioventricular conduction block, (8) QT interval prolongation (≥450 ms), (9) hypersensitivity to donepezil or piperidine derivatives, (10) severe parkinsonism (Hoehn and Yahr stage ≥ IV) [23] , and (11) treatment with ChEIs or any investigational drug within 3 months prior to screening. ChEIs, antipsychotics, and anti-Parkinson drugs other than levodopa or dopamine agonists were prohibited during the study. The following subjects were excluded from the present PK/pharmacodynamic analysis; those who did not take the study drug the day before plasma collection, those who took study drug just before plasma collection, and those whose drug compliance rate of b75%. The trial was conducted in 72 sites throughout Japan from 2011 to 2013 in accordance with the principles of the Declaration of Helsinki. The protocol was approved by the institutional review board at each participating center. Written informed consent was obtained from the patients (if at all possible) and from the primary caregiver.
Plasma concentration measurement
Plasma concentration was measured in patients who had at least one plasma sample collected at a steady state. Plasma was collected after 4, 8, and 12 weeks of treatment before taking donepezil, or at the time of discontinuation. Plasma donepezil concentrations were analyzed using a validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) method. Plasma donepezil concentrations of the placebo group were excluded from the analysis.
Factors affecting plasma donepezil concentration
The contributing factors affecting plasma donepezil concentration were explored using a multivariate regression analysis after selecting the factors to be included in the model. These factors were: dose (5 and 10 mg/day), patient demographics (sex, age, weight, CYP2D6 phenotype), and baseline characteristics (aspartate aminotransferase [AST], alanine aminotransferase [ALT], total bilirubin, albumin, alkaline phosphatase [ALP], creatinine clearance, concomitant CYP2D6 inhibitor, concomitant CYP3A4 inhibitor/inducer). The clinical laboratory data were categorized as normal or abnormal. One of the correlated variables was selected for multicollinearity analysis.
Exposure-response analysis
To investigate the relationship between plasma donepezil concentration and efficacy/safety, we analyzed patients who received donepezil for at least 4 weeks (3 mg/day for 2 weeks followed by 5 mg/day for 2 weeks), and who had one or more data of efficacy/safety parameters assessed at the same time point as plasma donepezil collection.
MMSE and NPI-2 scores, co-primary endpoints of the phase 3 RCT, were selected as efficacy parameters in this analysis. These were measured at Weeks 0, 4, 8, and 12, or at the time of discontinuation. The MMSE score was used to evaluate cognitive impairment. Scores ranged from 0 to 30, with higher scores indicating better cognitive function. The NPI-2 score was calculated as the sum of the hallucinations and cognitive fluctuation scores. Scores ranged from 0 to 24, with lower scores indicating improved neuropsychiatric symptoms.
Blood pressure (systolic or diastolic), pulse rate, body weight, and the Unified Parkinson's Disease Rating Scale (UPDRS) part III [24] were selected as safety parameters. These were measured at Weeks 0, 4, 8, and 12, or at the time of discontinuation, except UPDRS part III, which was measured at Weeks 0 and 12, or at the time of discontinuation, and evaluated the severity of parkinsonian symptoms. Scores ranged from 0 to 108, denoting "no" to "severe" symptoms, respectively.
Exposure-response analysis was performed using plasma donepezil concentration and changes from baseline of efficacy/safety parameters at Week 12, the last observation carried forward (LOCF), as responses. A scatter plot was used to illustrate the relationship between donepezil plasma concentrations and changes in efficacy/safety values at Week 12 (LOCF). After this, relationships between plasma concentrations and parameters were assessed by Pearson correlation. Statistical tests were two-tailed, and conducted with a significance level of 0.05.
Results
Patients
Overall, 87 patients (5 mg/day, 39; 10 mg/day, 48) were included in the exploratory analyses. Patient baseline demographic characteristics are shown in Table 1 . The mean (standard deviation, SD) age was 78.3 (6.2) years, the mean body weight was 51.6 (9.7) kg and 56.3% of participants were female. The baseline MMSE scores were 20.3 (4.5); NPI-2, 7.3 (4.7); and UPDRS part III, 19.7 (12.1).
Donepezil plasma concentration
Plasma donepezil concentrations at Weeks 4, 8 and 12 are shown in Fig. 1 . The mean (SD) plasma concentration (ng/mL) at Week 12 was 31.6 (11.8) for the 5 mg group and 65.3 (24.2) for the 10 mg group. The mean plasma concentration was proportionally higher in the 10 mg group than the 5 mg group at Weeks 8 and 12 (the dose was raised to 10 mg at Week 6 in the 10 mg group). As a whole, the donepezil plasma concentration ranged from 6.62-130.9 ng/mL at Week 12 (LOCF).
Factors affecting plasma donepezil concentration
Prior to multivariate regression analysis, we considered which factors should be included in the model. The ultra-rapid metabolizer (n = 2) and poor metabolizer (n = 0) of CYP2D6 phenotypes, and patients with concomitant use of CYP3A4 inducers (n = 2) were excluded because of an insufficient number of such patients. AST, ALT, and total bilirubin were excluded because most of the patients had normal values. The factors included in the model were the dose, age, CYP2D6 phenotype and concomitant use of CYP2D6 inhibitor (Table 2) . Creatinine clearance and age were highly correlated; age was selected for the analysis. The contribution rate of the model was estimated as 0.55 (p b 0.0001), and contributions of dose (contribution rate: 0.39, p b 0.0001) and of age (contribution rate: 0.12, p = 0.0003) were statistically significant. The observed plasma concentrations in 5 mg and 10 mg-treated patients categorized by age group (b74, 75-80, and N 80) are shown in Fig. 2 . Mean plasma concentration was higher in the 10 mg group than the 5 mg group in each age category, and increased with age (effect of dose: p b 0.001, effect of age: p = 0.015, and interaction term: not significant, two-way ANOVA). The effects of CYP2D6 phenotype and concomitant CYP2D6 inhibitors were marginally insignificant.
Exposure-efficacy analysis
Although the donepezil plasma concentration was broadly distributed in patients with raised MMSE scores, it was relatively low (b70 ng/mL) in patients whose MMSE score declined. MMSE scores were either raised or unchanged in all patients with higher plasma donepezil concentrations (≥70 ng/mL). Plasma donepezil concentration showed a statistically significant positive correlation with changes in the MMSE score (p = 0.040) (Fig. 3) . Similarly, the plasma donepezil concentration was distributed broadly in patients with an improved NPI-2 total score, hallucinations score, or cognitive fluctuation score (Fig. 4A, B 
Exposure-safety analysis
No correlation was observed between plasma donepezil concentration and systolic (p = 0.422) or diastolic blood pressure (p = 0.300), pulse rate (p = 0.433), or body weight (p = 0.558) (Fig. 5A-D) . Changes in the UPDRS part III total score did not correlate with the plasma donepezil concentration (p = 0.138). Additionally, patients with worsened UPDRS part III total scores did not show particularly high plasma donepezil concentrations (Fig. 6) .
Values evaluated at Week 12 (LOCF) are shown. Changes in safety parameters represent the difference between measurements at baseline and Week 12 (LOCF). The 10 mg/day dose was administered from Week 6. 
Discussion
This study, based on data derived from the phase 3 RCT of donepezil, showed that an increase in plasma donepezil concentration enhanced its positive effect on cognitive function without compromising safety. In the phase 2 RCT, 5 and 10 mg of donepezil were sufficient to significantly improve MMSE scores compared with the placebo group and 3 mg group [11] . In the phase 3 RCT, 10 mg donepezil significantly improved MMSE scores compared with the placebo group [9] , and increasing the dose to 10 mg from 5 mg further improved the MMSE score in the subsequent OLE phase [12] . These findings imply that increasing plasma donepezil concentration would further improve MMSE scores. We confirmed this in the present analysis. Donepezil 23 mg is currently available for moderate to severe AD in the US and other countries. The findings of the present study could be extrapolated to the higher dose; therefore, increasing higher doses might lead to further improvement of cognitive function also in DLB patients. Considering that the average weight of the Japanese patients is less than that of Western countries, this view would be particularly justified.
Patients with typical DLB symptoms and fewer concomitant Alzheimer's features (e.g., presence of hallucinations, larger hippocampal volume, low brain amyloid-β load) are likely to show a greater response to ChEIs [25, 26] . This may account for the variance of the response to donepezil, which weakens plasma concentration-response relationship.
Compared with the placebo group, the total NPI-2, hallucinations score, and cognitive fluctuation scores significantly improved in patients treated with 5 mg and 10 mg donepezil, and the improvements were dose-dependent in the phase 2 RCT [11] . Although PK sampling was not conducted in the phase 2 RCT, a correlation may have existed between plasma donepezil concentration and changes in the above symptoms. In the phase 3 RCT, all neuropsychiatric symptom scores improved with administration of 5 mg and 10 mg donepezil, but these improvements were not significantly different from the placebo group, owing to an unexpectedly high improvement in the placebo group [9] . Even in the present analysis, correlation of plasma concentration with NPI-2 scores, hallucinations score, or cognitive fluctuation score was not apparent. In addition to better non-pharmacological interventions and coping skills for behavioral and neuropsychological disorders of DLB possibly applied during the phase 3 RCT [9] , expectations or presumptions of caregivers and examiners in the phase 3 RCT may cause a positive bias. This is because the NPI is a structured interview given by the physician to the caregiver, the results of which are likely to be doubly affected by both examinee and examiner.
In the phase 2 RCT, blood pressure did not decrease in the 10 mg group, but did decrease in the 5 mg group after 12 weeks of donepezil treatment. In the phase 3 RCT, with an increasing dose of donepezil, blood pressure tended to decrease (Supplementary Table 1 ) and incidence of abnormal blood pressure reduction tended to increase (Supplementary Table 2 ). However, in the present PK/PD analysis, the changes in blood pressure were not significantly associated with the plasma donepezil concentration. Therefore, an increase in plasma donepezil concentration would not necessarily induce a decrement in blood pressure.
Theoretically, use of ChEIs may increase the risk of bradyarrhythmic events, to which DLB patients may be more susceptible than AD patients because of disease-specific autonomic dysfunction [16] . Donepezil administration to DLB patients has been reported to increase the risk of bradyarrhythmic or cardiovascular events [27, 17] . In fact, the mean change at Week 12 from baseline in pulse rate tended to decrease in the 10 mg group in phase 2 and 3 RCTs and the 5 mg group in the phase 3 RCT (Supplementary Table 1) . However, those studies reported only one abnormal change in pulse rate in the 10 mg group throughout the trials (Supplementary Table 2 ), and changes in pulse rate were not significantly associated with plasma donepezil concentration. These findings suggest that higher plasma donepezil concentrations induced by doses of up to 10 mg/day do not necessarily affect pulse rate or bradyarrhythmic events. This is consistent with previous investigations of rivastigmine, which did not affect the incidence of cardiovascularrelated adverse events [28] .
Body weight decreased slightly and to a similar extent in the 5 mg and 10 mg groups, but did not change in the placebo group (Supplementary Table 1 ). The rate of abnormal weight loss (N 7%) did not differ significantly in the 5 and 10 mg groups, but was higher than that of the placebo group (Supplementary Table 2 ). Although donepezil treatment appeared to be correlated with reduced body weight, this result was not concentration-dependent, and in fact, changes in body weight showed no statistically significant relationship with the plasma donepezil concentration. A decrease in body weight does not always imply an unfavorable effect due to loss of appetite, but could be a favorable effect due to increase of physical activity. Therefore, if there are no safety concerns including weight loss in patients administered a 5 mg/day dose, the risk of body weight loss may be low in these patients when increasing to 10 mg/day.
Although ChEI treatment can theoretically worsen extrapyramidal symptoms, the UPDRS part III scores were not significantly associated with the plasma donepezil concentration in the present analysis. This suggests that increasing the donepezil dose to 10 mg/day would not Fig. 2 . Observed plasma donepezil concentration by age in patients treated with 5 and 10 mg/day donepezil. Error bars indicate the standard deviation. 5 mg group: b74, n = 9; 75-80, n = 9; N80, n = 11. 10 mg group: b74, n = 14; 75-80, n = 14; N80, n = 10. necessarily exacerbate parkinsonism, as shown previously [9, 11, 29] . Although no correlation between plasma concentration and worsening of parkinsonism was not demonstrated, it is still important to observe parkinsonism during donepezil treatment in these patients.
In the PK analysis, the plasma donepezil concentration was proportional to the administered donepezil dose, in agreement with previous findings in healthy volunteers [30] . The mean plasma concentration was twice higher in patients in the 10 mg group than the 5 mg group, as expected. Dose was evidently the largest factor to determine the concentration. Considering the relationship between plasma concentration and safety results, it is worthwhile increasing the dose to 10 mg/day to increase plasma donepezil concentration for further improving cognitive function. Multivariate regression analysis showed that age was another significant determinant factor. There is a possibility that the donepezil plasma concentration become relatively low in lower age group (b 74) and relatively high in higher age group (N 80). As for factors of drug metabolism, although the effects of CYP2D6 phenotype and concomitant use of CYP2D6 inhibitors were marginal, type II error was likely because of a small sample size. In addition to the factors examined in this study, other factors may also influence the plasma donepezil concentration, such as drug compliance, interval between dosing and blood sampling, and so on. In any event, as dose explains only 39%, not only the dose but also various factors should be taken into consideration when discussing the dose-response relationship.
There are some limitations in the present study. First, as the sample size was not large, a caution should be paid for statistical power. Second, the multivariate regression model derived from the DLB patient population in this analysis may not necessarily be applicable to other DLB populations, including those that did not satisfy the inclusion criteria. For example, as patients with severe dementia of MMSE b 10 or with severe Parkinsonism of Hoehn and Yahr stage ≥ IV were not included, the findings are not generalizable to such patients. Finally, residual covariates may have affected plasma donepezil concentration, although we explored most of the generally known covariates.
Conclusion
The present study demonstrated that plasma donepezil concentration was affected mainly by dose, although age, possibly genetic factors, and other unknown factors are also determinants of it. An increase in plasma donepezil concentration enhances the improvement of cognitive function, not necessarily causing safety parameter worsening, which is consistent with the dose-response findings in the previous trials. For patients without safety concerns after administration of 5 mg/day donepezil, it is worth increasing the dose to 10 mg/day for the benefits of higher plasma donepezil concentrations on cognitive function. 
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